

Research Article

(Antral Follicle Count as predictor of ovarian response to controlled ovarian stimulation in IVF)

Hossam-Eldine Shawki, Mohammed T. Gad el Rab, Saad A. Ahmed, and Kareem I. Shahin.

Department of Obstetrics and Gynaecology of Minia University Hospital, Minia, Egypt.

Abstract

Objective: The present study aimed to evaluate the performance of uses of the most recently identified marker of ovarian reserve, namely antral follicle count (AFC), to categorize women based on their anticipated ovarian response. **Setting:** The study recruited patients referred for assisted reproduction treatment (ART) cycles to Minia infertility research unit (MIRU), Minia University Hospital, Minia, Egypt, during the period from October, 2013 to April, 2016 according to study protocol. **Study design:** Prospective observational analysis **Study participants:** This prospective study included a total of 119 women undergoing ICSI at Minia infertility research unit (MIRU), Minia University Hospital. **Results:** Univariate analyses showed that age, AFC and AMH were significant predictors for poor oocyte yield. AFC presented the highest ROCAUC of 0.77, indicating a good discriminating potential for predicting poor ovarian response, followed by AMH with an ROCAUC of 0.70. In the multivariate analysis, the AFC remained significant. **Conclusion:** Antral follicle count provided no added predictive value beyond AMH in prediction of ovarian response to gonadotropin therapy at the study utilizing GnRH agonist and GnRH antagonist protocols.

Keywords: antral follicle count (AFC), Ovarian response, IVF

Introduction

Since the birth of the first IVF baby in 1978, IVF results have much improved reaching an average of 30% pregnancy rate and 20% live birth rate per cycle. Central to this improvement in IVF performance was the shift in paradigm from natural unifollicular IVF cycles to multi follicular IVF cycles as data showed higher pregnancy rates with controlled ovarian hyperstimulation (Van Der vorst et al., 1997) However, the patients are exposed to the possibility of a low or excessive ovarian response.

Furthermore, the possibility of a negative impact of supraphysiological levels of estrogen resulting from the large numbers of follicles and oocytes on the embryo quality and/or the endometrium has been repeatedly questioned (Martinez 2007- Rubio C 2010). For this reason, knowledge of the patient's potential ovarian response can help clinicians individualize the medication dosage, which may reduce the adverse effects of an excessive ovarian response decrease the rate of cancelled cycles and ultimately, increase the pregnancy rate

The first indicator of the ovarian reserve taken into account is the patient's age. Although the number and quality of oocytes both decrease with age, the reproductive potential varies drastically among women of similar age; therefore, they might exhibit different responses to ovarian stimulation [Fauser BC et al., 2008].

Consequently, an individual's chronological age may not be as valuable a predictor of fertility as her "biological age", as defined by hormonal and functional profiles [Ezcurra D et al., 2012].

In fact, in addition to age, several clinical, endocrine and ultrasound markers, and dynamic tests have been proposed for the prediction of the ovarian response to stimulation [Broekmans 2006- Muttukrishna 2000].

Among these markers, use of the level of anti-Müllerian hormone (AMH) and the antral follicle count (AFC) is of particular

interest [Maheshwari et al., 2006]. The AFC consists of the sum of follicles < 10 mm in

both ovaries on a transvaginal ultrasound and has been used to predict the ovarian reserve and the patient response to ovarian stimulation.

However, there is significant variation among different authors in the limits used to classify antral follicles [Younis et al., 2010]. AMH, a member of the transforming growth factor-beta superfamily, is only produced by the granulosa cells surrounding the pre-antral and small antral follicles.

Additionally, AMH is independent of follicle stimulating hormone (FSH), whereby its levels are a direct measure of the follicular pool production. The serum levels of AMH decrease throughout reproductive life and are undetectable in the postmenopausal period [Younis et al., 2010]

In this study demonstrate that a derived multi-marker for measuring ovarian reserve was a good predictor for oocyte yield after ovulation induction and also for ongoing pregnancy, facilitate the optimization and individualization of assisted reproductive treatment before the onset of a treatment cycle and need to adapt approaches for patients sub-populations, and finally will consider the use of biomarkers as a tool for implementing an individualized approach to COS treatment protocols

Patients and methods

This prospective study included a total of 119 women undergoing ICSI at Minia infertility research unit (MIRU), Minia University Hospital **Eligability criteria:** All patients satisfied to the following Age less than 39 years, Regular menstrual cycle, Both ovaries present, No history of ovarian surgery, No evidence of endocrine disorder and only exclusion was presence of ovarian cysts as assessed by transvaginal ultrasound.

Plan of the study:

The 119 patients who agreed to participate, one withdrew before starting stimulation and two patients were canceled during

stimulation for the following reasons: wrong timing of hCG (one) and significant vaginal bleeding during stimulation (one). The remaining 116 women were classified into two groups.

(i) Group 1: Total number: 23

(a) Group 1A: represents those who were canceled during stimulation owing to poor response and did not proceed to hCG administration and oocyte collection (3 women).

(b) Group 1B: represents those who proceeded to oocyte retrieval and had ≤ 4 oocytes (20 women).

(ii) Group 2: Total number 93

(a) Group 2A: represents those who were deemed to have an excessive response to gonadotrophins and therefore had their cycle canceled before hCG because of risk of OHSS (one women).

(b) Group 2B: represents those who proceeded to oocyte retrieval and had > 4 oocytes (92 women).

Out of 112 who had oocyte retrieval, 32 women did not proceed to embryo transfer. One patient failed to have any oocytes collected and one woman had complete failure of fertilization. And one woman had elective cryopreservation of all embryos because of risk of OHSS

Clinical work-up:

Written informed Consent was obtained from all patients after giving verbal information about the aim of the study and the scan procedure involved in it.

All patients had comprehensive evaluation including full history taking, thorough physical examination and At the initial assessment special note was made of the following clinical features (age, cycle length, duration of subfertility, and body mass index (BMI).

Baseline pelvic ultrasound examination and evaluation of baseline hormonal profile namely FSH, LH and estradiol for prediction of ovarian response was done as part of the initial assessment during the follicular phase of spontaneous cycle.

The procedure for measuring the AFC was as follows:

A transverse section of the uterus was obtained, one ovary at a time was visualized by moving the probe laterally, adjustments to obtain a clear image of the ovary was done as required by changing the probe frequency, depth of focus or magnification. Each ovary was scanned in a systematic way by panning through the ovary up-down and from side to side. Antral follicles were defined as all echo lucent rounded structures measuring (2-10) mm seen within the ovarian substance. Serial scans were obtained by making a slow sweep with the transvaginal probe from the medial towards the lateral border of the ovary. As this sweep is performed through the whole ovary antral

follicles were assessed. Initially a note is made of follicles measuring 10 mm or larger. All follicle measurements were made on a frozen image, measuring both the antero-posterior and transverse planes and a mean diameter was calculated. Once a mental note was made of 10 mm size, all the antral follicles measuring smaller than 10mm (2-10) mm were counted and numbers recorded during a single sweep through the ovary. The procedure was repeated on the contralateral ovary to obtain the Total Antral follicles count (AFC) defined as the count of all antral follicles measuring (2-10) mm in both ovaries at the baseline examination (Bansci et al., 2002).

Results

Table (1): Predictors for poor response in women (≤4 oocytes) and for negative pregnancy outcome using univariate and multivariate logistic regression analysis.

Data		Odds ratio	95%CI	P	ROC AUC
For poor response	Univariate analysis				
	Age	1.2	1.1-1.3	0.001*	0.76
	BMI	1.04	0.92-1.1	0.7	0.51
	AFC	0.70	0.48-0.97	0.001*	0.11
	AMH	0.27	0.14-0.51	0.001*	0.10
	Multivariate analysis				
	Age	0.98	0.83-1.1	0.8	
	BMI	0.92	0.80-1.06	0.2	
AFC	0.71	0.44-0.80	0.004*		
AMH	0.93	0.38-2.2	0.8		
For negative pregnancy	Univariate analysis				
	Age	1.07	1-1.1	0.05	0.70
	BMI	1.001	0.93-1.07	0.9	0.51
	AFC	0.88	0.81-0.95	0.002*	0.30
	AMH	0.50	0.21-0.70	0.001*	0.26
	Multivariate analysis				
	Age	0.97	0.88-1.08	0.7	
	BMI	0.97	0.89-1.05	0.5	
AFC	1.001	0.88-1.1	0.9		
AMH	0.54	0.33-0.88	0.01*		

Univariate analyses showed that age, AFC and AMH were significant predictors for poor oocyte yield. AFC presented the highest ROCAUC of 0.11, indicating a good discriminating potential for predicting poor ovarian response, followed by AMH with an

ROCAUC of 0.10. In the multivariate analysis, the AFC remained significant. The results of univariate and multivariate logistic regression analyses showed that age was the only significant predictor for negative pregnancy outcome with an ROCAUC of 0.70.


Table (2): Comparison of performance characteristics for poor responders (≤ 4 oocytes) and for negative pregnancy Outcome.

Data	Cut off	sensitivity	Specificity
For poor response			
Age	22	70%	80.4%
BMI	23.0	00%	04.3%
AFC	8.0	10%	33%
AMH	1.00	40%	11%
For negative pregnancy			
Age	27	74.4%	40.3%
BMI	23.0	49.2%	04.7%
AFC	10.0	00.8%	22.6%
AMH	1.7	40.8%	11.3%

This table shows that the age was the only significant predictor for negative pregnancy outcome and none of the individual markers

of ovarian reserve were able to predict pregnancy. A maximized sensitivity of 70% and a specificity of 80.4% .

Figure (1) ROC curve analysis for AFC, AMH and Age as a prognostic factor regarding the clinical pregnancy:



AUC = 0.69 ± 0.00 (P=0.001*), Cutoff ≥ 10.0 (sensitivity = 76%, specificity of 61%).


AUC for AMH = 0.73 ± 0.04 (P=0.001*), Cutoff ≥ 2.3 (sensitivity = 77.8%, specificity of 63.8%)

AUC for Age = 0.07 ± 0.00 (P=0.1), Cutoff ≤ 30 (sensitivity = 74.1%, specificity of 41.4%)

Regarding the probability of pregnancy occurrence, performance of AMH using the ROC curve showed an area under the curve of 0.73 ± 0.04 ($P=0.001^*$), indicating that the AMH had a good prognostic potency for this point. Setting the specificity (73.8%) and sensitivity (77.8%).

ROC curves also revealed good prognostic potency for all other factors (Age and AFC) analysed. However, the AUC presented by the AMH was always higher than those presented by all other factors. Considering the ROC curves for the AMH level exhibited a good ability to predict clinical pregnancy.

Figure (2) distribution of studied group according to AFC number:



Discussion

The present study demonstrate that a derived multi-marker for measuring ovarian reserve was a good predictor for oocyte yield after ovulation induction and also for ongoing pregnancy, facilitate the optimization and individualization of assisted reproductive treatment before the onset of a treatment cycle and need to adapt approaches for patients sub-populations, and finally will consider the use of biomarkers as a tool for implementing an individualized approach to COS treatment protocols.

AMH, produced by granulosa cells of pre-antral and small antral follicles, has emerged as a useful marker of ovarian function. AMH has been used in assessment of ovarian aging, prediction of response to ovulation induction and the assessment of the risk of developing OHSS (Van Rooij et al., 2002; Nelson et al., 2007).

Our study clearly demonstrated the superiority of AMH in prediction of good response compared with the other individual markers (AUC for age: 0.57; AFC : 0.69;

AMH: 0.73) Nelson et al. (2009) investigated the role of AMH in predicting oocyte yield, showing that the use of circulating AMH concentration to individualize treatment strategies for controlled ovarian stimulation reduced clinical risk of OHSS whilst optimizing pregnancy rates.

Our study has shown that AMH in predicting oocyte yield (AUC for AMH: 0.73) but superior in predicting pregnancy outcome compared to age and antral follicle count.

The finding that AMH was a more robust biomarker of the ovarian response to gonadotropins than AFC was also confirmed in the present study, The regression analysis for AMH and number of oocytes retrieved was higher in collecting ≤ 4 oocytes (OR: 3.7; $P < 0.001$), ≤ 4 metaphase II oocytes (OR: 2.1; $P < 0.01$) and ≤ 10 oocytes (OR: 2.4; $P < 0.001$).

Alternativel, regardless of the protocol and the different gonadotropin doses used, because the treatment effect was constant

for both AMH and AFC, it would not be expected to alter the strength of association for the two biomarkers.

Also we have demonstrated that AMH value was the most accurate predictor of poor response amongst other competing parameters tested. This was followed by age, and AFC. This implies that using AMH and age might improve the possibility of forecasting poor ovarian response in a higher proportion of patients over what is currently possible using the standard predictors as age, basal FSH, E2. However, on multivariate logistic regression analysis, only AFC stand out as the significant predictors of poor ovarian response after adjusting for potential impact of other confounding predictors whereas other factors as age and AMH levels were insignificant. On the other hand, in our analysis, BMI were inaccurate and insignificant predictors of poor response

References

1. Martinez-Conejero JA, Simon C, Pellicer A, Horcajadas JA: Is ovarian stimulation detrimental to the endometrium? *Reprod Biomed Online* 2007, 15:40-50.
2. Rubio C, Mercader A, Alama P, Lizan C, Rodrigo L, Labarta E, Melo M, Pellicer A, Remohi J: Prospective cohort study in high responder oocyte donors using two hormonal stimulation protocols: impact on embryo aneuploidy and development. *Hum Reprod* 2010, 25:2290-2297.
3. Fauser BC, Diedrich K, Devroey P: Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. *Hum Reprod Update* 2008, 14:1-14.
4. Alviggi C, Humaidan P, Ezcurra D: Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. *Reprod Biol Endocrinol* 2012, 10:9.
5. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB: A systematic review of tests predicting ovarian reserve and IVF outcome. *Hum Reprod Update* 2006, 12:780-718.
6. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P: Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? *BJOG* 2000, 112:1384-1390.
7. Maheshwari A, Fowler P, Bhattacharya S: Assessment of ovarian reserve—should we perform tests of ovarian reserve routinely? *Hum Reprod* 2006, 21:2729-2730.
8. Younis JS, Jadaon J, Izhaki I, Haddad S, Radin O, Bar-Ami S, Ben-Ami M: A simple multivariate score could predict ovarian reserve, as well as pregnancy rate, in infertile women. *Fertil Steril* 2010, 94:700-711.
9. Van DerVorst M, Joris H, Van Steirteghem A: correlation between ongoing pregnancy rates and the number of cumulus oocytes retrieved in agonist—HMG stimulated ICSI cycles *Hum Reprod* 1997; 12:168-9
10. Van Rooij IA, Broekmans FJ, te Velde ER.: Serum antimüllerian hormone a novel measure of ovarian reserve. *Hum Reprod* 2002, 17:3060-3071.
11. Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. *Hum Reprod* 2007; 22:2414-2421.
12. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. *Hum Reprod* 2009; 24:867-870.
13. Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD and te Velde ER (2002) Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. *Fertil Steril* 77, 328-336.